TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06868732: Evaluation of JSKN016 Combination Therapy in Subjects With Advanced Non-Small Cell Lung Cancer: A Phase Ib Study

Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 288 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT06868732 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06868732 Rescue Dossier →